• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Datavant & Boehringer Ingelheim Expand RWE Partnership for 75+ Clinical Trials

by Syed Hamza Sohail 05/05/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

–  Datavant, a leading health data platform, has announced an expanded collaboration with Boehringer Ingelheim to strengthen the pharmaceutical company’s real-world evidence (RWE) capabilities.

–  This partnership aims to advance clinical development and commercial strategy across 75 additional clinical trials and multiple new molecular entities (NMEs), leveraging Datavant’s cutting-edge privacy-preserving tokenization and data connectivity technologies.

Datavant and Boehringer Ingelheim Expand Partnership to Advance Scalable Real-World Evidence Ecosystem

The expanded collaboration highlights the growing importance of secure, connected data in transforming patient care. By utilizing Datavant Connect powered by AWS Clean Rooms, Boehringer Ingelheim will:

  • Efficiently explore and assess third-party data sources without transferring or sharing underlying data
  • Streamline data discovery, transformation, and linkage within its secure research environment
  • Enhance insights across the patient journey, from clinical development to post-launch performance

Arnaub Chatterjee, President and GM of Life Sciences, Ecosystem, and Public Sector at Datavant, noted:
“We are honored to support Boehringer Ingelheim in revolutionizing patient care through a pioneering data strategy. By enabling secure and efficient data linkage at scale, Boehringer Ingelheim is setting a new benchmark for medical research and demonstrating how technology can reshape healthcare and improve outcomes.”

Boehringer Ingelheim’s Executive Director and Head of the Real World Evidence Analytics Center of Excellence, Paul Petraro, underscored the strategic importance of the partnership:
“Our investment in real-world data reflects Boehringer Ingelheim’s commitment to advancing medical research with cutting-edge technologies. By expanding this approach across more trials and launches, we aim to drive more personalized, cost-effective treatments that transform patient care.”

To integrate seamlessly with Boehringer Ingelheim’s research infrastructure, the teams will implement tokenization through a phased rollout. Key goals of the initiative include:

  • Establishing a robust framework to guide future studies
  • Demonstrating value to industry peers considering cloud-based tokenization and real-world evidence strategies
  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Real World Evidence (RWE)

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |